$599

Merck Enters Licensing Agreement for Oral Lp(a)

Merck and Jiangsu Hengrui Pharmaceuticals announced an exclusive licensing agreement for HRS-5346, an oral small molecule Lp(a) inhibitor. Below, FENIX provides insights and highlights into the agreement.

This content is for Read Less members only.
Register
Already a member? Log in here